Impact of Initiating Biologics in Patients With Severe Asthma on Long-Term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER): Data From the International Severe Asthma Registry

• Type: Article in International Scientific Journal
• Date: 2023

Authors

Chen, WJ (Author) Other; Tran, TN (Author) Other; Sadatsafavi, M (Author) Other; Murray, R (Author) Other; Wong, NCB (Author) Other; Ali, N (Author) Other; Ariti, C (Author) Other; Bulathsinhala, L (Author) Other; Garcia, E (Author) Other; FitzGerald, JM (Author) Other; Alacqua, M (Author) Other; Al-Ahmad, M (Author) Other; Altraja, A (Author) Other; Al-Lehebi, R (Author) Other; Bhutani, M (Author) Other; Bjermer, L (Author) Other; Bjerrum, AS (Author) Other; Bourdin, A (Author) Other; von Bülow, A (Author) Other; Busby, J (Author) Other; Canonica, GW (Author) Other; Carter, V (Author) Other; Christoff, GC (Author) Other; Cosio, BG (Author) Other; Costello, RW (Author) Other; Fonseca, J (Author) FMUP; Gibson, PG (Author) Other; Yoo, KH (Author) Other; Heaney, LG (Author) Other; Heffler, E (Author) Other; Hew, M (Author) Other; Hilberg, O (Author) Other; Hoyte, F (Author) Other; Iwanaga, T (Author) Other; Jackson, DJ (Author) Other; Jones, RC (Author) Other; Koh, MS (Author) Other; Kuna, P (Author) Other; Larenas-Linnemann, D (Author) Other; Lehmann, S (Author) Other; Lehtimäki, L (Author) Other; Lyu, J (Author) Other; Mahboub, B (Author) Other; Maspero, J (Author) Other; Menzies-Gow, AN (Author) Other; Newell, A (Author) Other; Sirena, C (Author) Other; Papadopoulos, NG (Author) Other; Papaioannou, AI (Author) Other; Perez-de-Llano, L (Author) Other; Perng, DW (Author) Other; Peters, M (Author) Other; Pfeffer, PE (Author) Other; Porsbjerg, CM (Author) Other; Popov, TA (Author) Other; Rhee, CK (Author) Other; Salvi, S (Author) Other; Taillé, C (Author) Other; Taube, C (Author) Other; Torres-Duque, CA (Author) Other; Ulrik, C (Author) Other; Ra, SW (Author) Other; Wang, E (Author) Other; Wechsler, ME (Author) Other; Price, DB (Author) Other

Journal

Title: Journal of Allergy and Clinical Immunology: In Practice

Vol. 11

Pages: 2732-2747

ISSN: 2213-2198

Publisher: Elsevier

Indexing

ISI Web of Knowledge - 11 Citations

Scopus - 11 Citations

Other information

Authenticus ID: P-00Y-RGF

DOI: 10.1016/j.jaip.2023.05.044

Abstract (EN): BACKGROUND: Effectiveness of biologics has neither been established in patients with high oral corticosteroid exposure (HOCS) nor been compared with effectiveness of continuing with HOCS alone. OBJECTIVE: To examine the effectiveness of initiating biologics in a large, real-world cohort of adult patients with severe asthma and HOCS. METHODS: This was a propensity scoreematched, prospective cohort study using data from the International Severe Asthma Registry. Between January 2015 and February 2021, patients with severe asthma and HOCS (long-term OCSs for >= 1 year or >= 4 courses of rescue OCSs within a 12-month period) were identified. Biologic initiators were identified and, using propensity scores, matched 1:1 with noninitiators. The impact of biologic initiation on asthma outcomes was assessed using generalized linear models. RESULTS: We identified 996 matched pairs of patients. Both groups improved over the 12-month follow-up period, but improvement was greater for biologic initiators. Biologic initiation was associated with a 72.9% reduction in the average number of exacerbations per year versus noninitiators (0.64 vs 2.06; rate ratio, 0.27 [95% CI, 0.10-0.71]). Biologic initiators were 2.2 times more likely than noninitiators to take a daily long-term OCS dose of less than 5 mg (risk probability, 49.6% vs 22.5%; P [.002) and had a lower risk of asthma-related emergency department visits (relative risk, 0.35 [95% CI, 0.21-0.58]; rate ratio, 0.26 [0.14-0.48]) and hospitalizations (relative risk, 0.31 [95% CI, 0.18-0.52]; rate ratio, 0.25 [0.13-0.48]). CONCLUSIONS: In a real-world setting, including patients with severe asthma and HOCS from 19 countries, and within an environment of clinical improvement, initiation of biologics was associated with further improvements across multiple asthma outcomes, including exacerbation rate, OCS exposure, and health care resource utilization. (C) 2023 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 16